RU2020112558A - Терапия на основе ингибитора глутаминазы - Google Patents
Терапия на основе ингибитора глутаминазы Download PDFInfo
- Publication number
- RU2020112558A RU2020112558A RU2020112558A RU2020112558A RU2020112558A RU 2020112558 A RU2020112558 A RU 2020112558A RU 2020112558 A RU2020112558 A RU 2020112558A RU 2020112558 A RU2020112558 A RU 2020112558A RU 2020112558 A RU2020112558 A RU 2020112558A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- cycloalkyl
- groups
- heteroaryl
- aryl
- Prior art date
Links
- 229940121727 Glutaminase inhibitor Drugs 0.000 title claims 4
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 14
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- -1 alkilarilalkila Chemical group 0.000 claims 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 8
- KLQLQDLJJUAEGT-ZBFHGGJFSA-N CO[C@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC=CC=1)C1=CC=CC=C1 Chemical compound CO[C@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC=CC=1)C1=CC=CC=C1 KLQLQDLJJUAEGT-ZBFHGGJFSA-N 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 claims 5
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 claims 5
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 108010024636 Glutathione Proteins 0.000 claims 4
- 229960003180 glutathione Drugs 0.000 claims 4
- 101710184006 Glutaminase 1 Proteins 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 238000011532 immunohistochemical staining Methods 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- MDJIPXYRSZHCFS-UHFFFAOYSA-N 2-phenyl-n-[5-[2-[2-[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]ethylsulfanyl]ethyl]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound N=1N=C(CCSCCC=2SC(NC(=O)CC=3C=CC=CC=3)=NN=2)SC=1NC(=O)CC1=CC=CC=C1 MDJIPXYRSZHCFS-UHFFFAOYSA-N 0.000 claims 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 2
- 125000006456 halo alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000003106 haloaryl group Chemical group 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 238000002626 targeted therapy Methods 0.000 claims 2
- ZIJSXWATZIIXHV-OAHLLOKOSA-N 1-[(2R)-2-fluoro-4-[6-[[2-[1-[3-(trifluoromethoxy)phenyl]imidazol-4-yl]acetyl]amino]pyridazin-3-yl]butyl]-N-methyltriazole-4-carboxamide Chemical compound CNC(=O)C1=CN(C[C@H](F)CCC2=CC=C(NC(=O)CC3=CN(C=N3)C3=CC(OC(F)(F)F)=CC=C3)N=N2)N=N1 ZIJSXWATZIIXHV-OAHLLOKOSA-N 0.000 claims 1
- COONWMQDDZPOJM-GOSISDBHSA-N 1-[(2R)-2-fluoro-4-[6-[[2-[4-[3-(trifluoromethoxy)phenyl]pyridin-2-yl]acetyl]amino]pyridazin-3-yl]butyl]-N-methyltriazole-4-carboxamide Chemical compound CNC(=O)C1=CN(C[C@H](F)CCC2=CC=C(NC(=O)CC3=NC=CC(=C3)C3=CC(OC(F)(F)F)=CC=C3)N=N2)N=N1 COONWMQDDZPOJM-GOSISDBHSA-N 0.000 claims 1
- RJBJVXJTSXXWHJ-CQSZACIVSA-N 1-[(2R)-2-fluoro-4-[6-[[2-[6-methyl-4-(trifluoromethyl)pyridin-2-yl]acetyl]amino]pyridazin-3-yl]butyl]-N-methyltriazole-4-carboxamide Chemical compound CNC(=O)C1=CN(C[C@H](F)CCC2=CC=C(NC(=O)CC3=NC(C)=CC(=C3)C(F)(F)F)N=N2)N=N1 RJBJVXJTSXXWHJ-CQSZACIVSA-N 0.000 claims 1
- VXIUYRWWCVVJHT-MRXNPFEDSA-N 1-[(2R)-4-[6-[[2-(4-cyclopropylpyridin-2-yl)acetyl]amino]pyridazin-3-yl]-2-fluorobutyl]-N-methyltriazole-4-carboxamide Chemical compound CNC(=O)C1=CN(C[C@H](F)CCC2=CC=C(NC(=O)CC3=NC=CC(=C3)C3CC3)N=N2)N=N1 VXIUYRWWCVVJHT-MRXNPFEDSA-N 0.000 claims 1
- KYYPZVRDPNETHK-CQSZACIVSA-N 1-[(2R)-4-[6-[[2-[4-(3,3-difluorocyclobutyl)oxypyridin-2-yl]acetyl]amino]pyridazin-3-yl]-2-fluorobutyl]-N-methyltriazole-4-carboxamide Chemical compound FC1(CC(C1)OC1=CC(=NC=C1)CC(=O)NC1=CC=C(N=N1)CC[C@H](CN1N=NC(=C1)C(=O)NC)F)F KYYPZVRDPNETHK-CQSZACIVSA-N 0.000 claims 1
- VPIDRKJHXQPVPF-MRXNPFEDSA-N 1-[(2R)-4-[6-[[2-[4-[cyclopropyl(difluoro)methyl]pyridin-2-yl]acetyl]amino]pyridazin-3-yl]-2-fluorobutyl]-N-methyltriazole-4-carboxamide Chemical compound C1(CC1)C(C1=CC(=NC=C1)CC(=O)NC1=CC=C(N=N1)CC[C@H](CN1N=NC(=C1)C(=O)NC)F)(F)F VPIDRKJHXQPVPF-MRXNPFEDSA-N 0.000 claims 1
- PMIAKXRPJSPNMJ-UHFFFAOYSA-N 1-[2-fluoro-4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]-N-[[4-(trifluoromethyl)pyridin-2-yl]methyl]triazole-4-carboxamide Chemical compound FC(CCC1=NN=C(NC(=O)CC2=NC=CC=C2)S1)CN1C=C(N=N1)C(=O)NCC1=NC=CC(=C1)C(F)(F)F PMIAKXRPJSPNMJ-UHFFFAOYSA-N 0.000 claims 1
- FSPSNRJKBCEPED-UHFFFAOYSA-N 1-[4-[6-[[2-(4-cyclobutyloxypyridin-2-yl)acetyl]amino]pyridazin-3-yl]-2-fluorobutyl]-N-methyltriazole-4-carboxamide Chemical compound CNC(=O)C1=CN(CC(F)CCC2=CC=C(NC(=O)CC3=NC=CC(OC4CCC4)=C3)N=N2)N=N1 FSPSNRJKBCEPED-UHFFFAOYSA-N 0.000 claims 1
- PESAWHFVOHIWKH-UHFFFAOYSA-N 1-[4-[6-[[2-(4-cyclobutyloxypyridin-2-yl)acetyl]amino]pyridazin-3-yl]butyl]-N-methyltriazole-4-carboxamide Chemical compound C1(CCC1)OC1=CC(=NC=C1)CC(=O)NC1=CC=C(N=N1)CCCCN1N=NC(=C1)C(=O)NC PESAWHFVOHIWKH-UHFFFAOYSA-N 0.000 claims 1
- KYYPZVRDPNETHK-UHFFFAOYSA-N 1-[4-[6-[[2-[4-(3,3-difluorocyclobutyl)oxypyridin-2-yl]acetyl]amino]pyridazin-3-yl]-2-fluorobutyl]-N-methyltriazole-4-carboxamide Chemical compound FC1(CC(C1)OC1=CC(=NC=C1)CC(=O)NC1=CC=C(N=N1)CCC(CN1N=NC(=C1)C(=O)NC)F)F KYYPZVRDPNETHK-UHFFFAOYSA-N 0.000 claims 1
- UXVCEKRAZBZVSL-UHFFFAOYSA-N 2-pyridin-2-ylacetamide Chemical compound NC(=O)CC1=CC=CC=N1 UXVCEKRAZBZVSL-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- HNAUHXMQQVBXLM-UHFFFAOYSA-N 5-[3-[6-[(2-pyridin-2-ylacetyl)amino]pyridazin-3-yl]pyrrolidin-1-yl]-N-[[4-(trifluoromethyl)pyridin-2-yl]methyl]-1,3,4-thiadiazole-2-carboxamide Chemical compound N1=C(C=CC=C1)CC(=O)NC1=CC=C(N=N1)C1CN(CC1)C1=NN=C(S1)C(=O)NCC1=NC=CC(=C1)C(F)(F)F HNAUHXMQQVBXLM-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- UHINPSCGZCGGOV-UHFFFAOYSA-N N-methyl-1-[4-[6-[[2-[4-[3-(trifluoromethoxy)phenyl]pyridin-2-yl]acetyl]amino]pyridazin-3-yl]butyl]triazole-4-carboxamide Chemical compound CNC(=O)C=1N=NN(C=1)CCCCC=1N=NC(=CC=1)NC(CC1=NC=CC(=C1)C1=CC(=CC=C1)OC(F)(F)F)=O UHINPSCGZCGGOV-UHFFFAOYSA-N 0.000 claims 1
- GLBIUCSKLWEPNJ-UHFFFAOYSA-N N1=C(C=CC=C1)CNC(=O)C=1SC(=NN=1)N1CC(CC1)C=1N=NC(=CC=1)NC(CC1=CC(=CC=C1)OC(F)(F)F)=O Chemical compound N1=C(C=CC=C1)CNC(=O)C=1SC(=NN=1)N1CC(CC1)C=1N=NC(=CC=1)NC(CC1=CC(=CC=C1)OC(F)(F)F)=O GLBIUCSKLWEPNJ-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0408—Phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573906P | 2017-10-18 | 2017-10-18 | |
| US62/573,906 | 2017-10-18 | ||
| PCT/US2018/056567 WO2019079632A1 (en) | 2017-10-18 | 2018-10-18 | GLUTAMINASE INHIBITOR THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020112558A true RU2020112558A (ru) | 2021-11-18 |
| RU2020112558A3 RU2020112558A3 (enExample) | 2022-03-21 |
Family
ID=66173506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020112558A RU2020112558A (ru) | 2017-10-18 | 2018-10-18 | Терапия на основе ингибитора глутаминазы |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10722487B2 (enExample) |
| EP (1) | EP3697764B1 (enExample) |
| JP (1) | JP7361687B2 (enExample) |
| CN (1) | CN111225903B (enExample) |
| ES (1) | ES3040089T3 (enExample) |
| RU (1) | RU2020112558A (enExample) |
| WO (1) | WO2019079632A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6619758B2 (ja) | 2014-07-03 | 2019-12-11 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 疾患を処置するためのｇｌｓ１阻害薬 |
| ES2794868T3 (es) | 2015-06-30 | 2020-11-19 | Univ Texas | Inhibidores de GLS1 para el tratamiento de enfermedades |
| SG11201804664XA (en) | 2015-12-22 | 2018-07-30 | Univ Texas | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
| EP3697764B1 (en) | 2017-10-18 | 2025-06-11 | Board Of Regents, The University Of Texas System | Gls-1 inhibitors for use in the treatment of cancer |
| US20250275964A1 (en) * | 2019-10-15 | 2025-09-04 | Cornell University | Methods of inhibiting liver-type glutaminase, gls2 |
| CN112791087B (zh) * | 2020-06-05 | 2023-06-30 | 厦门大学附属中山医院 | Bptes在制备预防或治疗炭疽病的药物中的用途 |
| CN117043153A (zh) * | 2020-12-11 | 2023-11-10 | 杭州紫晶医药科技有限公司 | 作为gls1抑制剂的杂环化合物 |
| JP2025078888A (ja) * | 2022-01-28 | 2025-05-21 | 国立大学法人富山大学 | グルタミナーゼ阻害剤 |
| KR102842785B1 (ko) * | 2022-09-07 | 2025-08-07 | 재단법인 아산사회복지재단 | 선행화학요법 내성의 고형암 환자 진단용 바이오마커 및 이를 이용한 선행화학요법 내성 진단을 위한 정보제공방법 |
| CN119326875A (zh) * | 2024-12-23 | 2025-01-21 | 中国人民解放军总医院第三医学中心 | L-ASNase在制备治疗膀胱癌药物中的应用及试剂盒 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES498337A0 (es) | 1980-01-07 | 1982-06-01 | Nyegaard & Co As | Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas |
| EP0218753B1 (en) | 1985-10-10 | 1989-08-09 | Agfa-Gevaert N.V. | Image-recieving element for the silver salt diffusion transfer reversal process |
| WO1991009848A1 (en) | 1989-12-22 | 1991-07-11 | The Upjohn Company | Pyridinones useful as antiatherosclerotic agents |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| IL122782A (en) | 1995-07-21 | 2003-03-12 | Gruppe Constantia | Triazole salts and pharmaceutical compositions containing the same and methods for evaluating the susceptibility of a cancer to growth inhibition utilizing the same |
| US6214834B1 (en) | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
| JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類 |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| SG168422A1 (en) * | 2001-11-13 | 2011-02-28 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| WO2007103290A2 (en) * | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CA2686933A1 (en) | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| PL2247592T3 (pl) | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
| PL2300013T5 (pl) | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| RU2544010C2 (ru) | 2009-02-27 | 2015-03-10 | Энанта Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
| JP5725475B2 (ja) | 2010-01-21 | 2015-05-27 | 公立大学法人名古屋市立大学 | ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤 |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| WO2013078123A1 (en) | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| RS62447B1 (sr) | 2012-11-16 | 2021-11-30 | Calithera Biosciences Inc | Heterociklični inhibitori glutaminaze |
| EP2922832B1 (en) | 2012-11-21 | 2019-10-09 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| CA2892817A1 (en) | 2012-12-03 | 2014-06-12 | Calithera Biosciences Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| EP2952096B1 (en) | 2013-01-30 | 2018-04-04 | Sumitomo Chemical Company, Limited | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest |
| TW201500356A (zh) | 2013-04-12 | 2015-01-01 | Lilly Co Eli | 二氫吡啶并嘧啶化合物 |
| CN105960405B (zh) | 2014-01-06 | 2021-02-19 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| US20160058759A1 (en) | 2014-07-03 | 2016-03-03 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| JP6619758B2 (ja) | 2014-07-03 | 2019-12-11 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 疾患を処置するためのｇｌｓ１阻害薬 |
| WO2016004413A2 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
| WO2016004418A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| WO2016004417A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
| ES2794868T3 (es) | 2015-06-30 | 2020-11-19 | Univ Texas | Inhibidores de GLS1 para el tratamiento de enfermedades |
| SG11201804664XA (en) | 2015-12-22 | 2018-07-30 | Univ Texas | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
| EP3697764B1 (en) | 2017-10-18 | 2025-06-11 | Board Of Regents, The University Of Texas System | Gls-1 inhibitors for use in the treatment of cancer |
-
2018
- 2018-10-18 EP EP18868394.0A patent/EP3697764B1/en active Active
- 2018-10-18 JP JP2020521600A patent/JP7361687B2/ja active Active
- 2018-10-18 WO PCT/US2018/056567 patent/WO2019079632A1/en not_active Ceased
- 2018-10-18 CN CN201880067288.0A patent/CN111225903B/zh active Active
- 2018-10-18 US US16/164,581 patent/US10722487B2/en active Active
- 2018-10-18 ES ES18868394T patent/ES3040089T3/es active Active
- 2018-10-18 RU RU2020112558A patent/RU2020112558A/ru unknown
-
2020
- 2020-06-03 US US16/891,791 patent/US11045443B2/en active Active
-
2021
- 2021-05-21 US US17/327,225 patent/US11786500B2/en active Active
-
2023
- 2023-09-06 US US18/461,724 patent/US12336976B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10722487B2 (en) | 2020-07-28 |
| JP2021500335A (ja) | 2021-01-07 |
| EP3697764A4 (en) | 2021-07-21 |
| US20190274993A1 (en) | 2019-09-12 |
| US20240165070A1 (en) | 2024-05-23 |
| RU2020112558A3 (enExample) | 2022-03-21 |
| ES3040089T3 (en) | 2025-10-28 |
| EP3697764B1 (en) | 2025-06-11 |
| US11786500B2 (en) | 2023-10-17 |
| CN111225903A (zh) | 2020-06-02 |
| EP3697764A1 (en) | 2020-08-26 |
| WO2019079632A1 (en) | 2019-04-25 |
| US12336976B2 (en) | 2025-06-24 |
| US20200368196A1 (en) | 2020-11-26 |
| CN111225903B (zh) | 2024-08-16 |
| US20220016069A1 (en) | 2022-01-20 |
| US11045443B2 (en) | 2021-06-29 |
| JP7361687B2 (ja) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020112558A (ru) | Терапия на основе ингибитора глутаминазы | |
| Chen et al. | Treatment landscape of renal cell carcinoma | |
| JP2021500335A5 (enExample) | ||
| Wang et al. | Consensus, debate, and prospective on pancreatic cancer treatments | |
| Farrow et al. | Autophagy as a modulator and target in prostate cancer | |
| Wu et al. | Overcoming treatment resistance in cancer: Current understanding and tactics | |
| Corona et al. | CDK4/6 inhibitors in HER2-positive breast cancer | |
| Yardley | Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions | |
| JP2014518544A5 (enExample) | ||
| ES2639402T3 (es) | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JP2010510319A5 (enExample) | ||
| RU2010150786A (ru) | Пирролопиридины как ингибиторы киназы | |
| JP2015523390A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| JP2023162250A (ja) | がんの治療のためのｎｏｘ阻害剤の使用 | |
| JP2017502967A5 (enExample) | ||
| KR20140025427A (ko) | 치환된 2,3-디하이드로이미다조[1,2-c]퀴나졸린의 용도 | |
| AU2016231260A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| Butt et al. | Role of mTORC1 and mTORC2 in breast cancer: therapeutic targeting of mTOR and its partners to overcome metastasis and drug resistance | |
| RU2019117958A (ru) | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| JP2018501261A5 (enExample) | ||
| RU2017110535A (ru) | Пиразолотиазоловое соединение и содержащее его лекарственное средство | |
| Kanji et al. | Gemcitabine and taxane adjuvant therapy with chemoradiation in resected pancreatic cancer: A novel strategy for improved survival? |